Labquality participates in the quality assessment of laboratory tests during a vaccine study in Benin.
The University of Helsinki studies orally administered ETVAX diarrhea vaccine in cooperation with Scandinavian Biopharma. The research project partner United Medix Laboratories Ltd (UML) has set up a special laboratory for the study in Benin, where preliminary analyses of samples from the test subjects are carried out. The samples are sent to UML’s central laboratory in Finland for verification and further analyses.
Labquality participates in the project by providing external quality assessment for the laboratory tests analyzed by culture both in Benin and at UML’s central laboratory in Finland.
The aim of the vaccine study is to protect against diarrhea caused by E. coli (ETEC) bacteria. The efficacy and safety of the vaccine are tested in the research project. The test subjects are healthy adult Finnish volunteers, who travel to Benin during the study.
In addition to the study, Labquality and UML offer a Beninese laboratory free quality assessment services and related support in developing laboratory activities locally.
Labquality’s CEO Mia Lindström is satisfied with the cooperation.
– The reliability of laboratory tests plays a central role for the success of the vaccine study. Furthermore, I am especially happy that Labquality participates in the development of laboratory activities in Benin in addition to this important project.
More information:
Labquality’s CEO Mia Lindström, tel. +358 50 3636 595, mia.lindstrom@labquality.fi
United Medix Laboratories Ltd’s medical director Sakari Jokiranta, tel. +358 50 547 1184, sakari.jokiranta@medix.fi, www.yml.fi
